Cancer News and Research

Latest Cancer News and Research

Breath test to detect cancer: Study

According to researchers cancer may soon be detectable using a breath test. They are now developing sensors that can detect chemical markers of lung, breast, bowel and prostate cancer in a person's breath. The new portable device has been purported as an “electronic nose” that can detect early cancers. As a cancer grows, the surface of the cells emits chemicals. The research found that sensors – involving gold nanoparticles – could be used to detect these chemicals in the breath.

10 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Arrowhead Research signs option agreement for new technology platform to kill fat tissue

Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.

10 Aug 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2010.

10 Aug 2010

First Edition: August 10, 2010

In today's news, the House is back in town... though just for a day. Lawmakers will consider a state aid package that includes $16 billion in federal Medicaid assistance.

10 Aug 2010

Scientists identify compound to inhibit wild-type HIV-1 protease

Drug resistance remains a major problem in combating HIV infection, but a different approach to drug development could be the answer.Current viral inhibitors target the HIV-1 protease function with a competitive mechanism. Writing in the BJ ChemBio Knowledge Environment of the Biochemical Journal, Max Chang and colleagues from the Scripps Research Institute, La Jolla, suggest that pharmaceutical companies look at compounds that use an allosteric non-competitive mechanism of inhibition.

10 Aug 2010

Olympus America introduces new V-System for ERCP procedure

Olympus America Inc., a precision technology leader designing and delivering innovative solutions in medical and surgical products among other core business areas, today launched its new V-System. The new V-System combines Olympus' latest duodenoscope, the TJF-Q180V, with its unique V-System devices for the endoscopic retrograde cholangiopancreatography procedure.

From Evident Corporation - Life Sciences 10 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Calif. considers reduction in funding for home care aides; Ill. union workers strike over health issues at uranium conversion plant

California, facing a $19.1 billion budget gap, is considering a reduction in funding that pays for home care aides for the disabled. It already cut funds last year. … Last month, the nation celebrated the 20th anniversary of the Americans With Disabilities Act … Now, though, gains made under the ADA are running into recession-battered state budgets.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd - Cancer Research UK's commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

10 Aug 2010

Raptor Pharmaceutical to raise $15 million through PIPE financing

Raptor Pharmaceutical Corp., announced it has entered into a securities purchase agreement in connection with a private placement, or PIPE financing. Upon the closing of the PIPE financing, Raptor will receive gross proceeds of approximately $15 million resulting from the sale of 4,897,614 units at a purchase price of $3.075 per unit.

10 Aug 2010

Computerized warning system alerts harmful drug orders for older hospital patients

Adverse drug events, such as dizziness or confusion occur in an estimated 40 percent of all hospital patients and can be the result of inappropriate medications being ordered. Not surprisingly, elderly individuals are particularly vulnerable to these adverse events, which not only result in longer hospitalizations, but can also pose a threat of serious complications and even death.

10 Aug 2010

Brain-wave pattern study may lead to techniques for enhancing sleep spindles

People who have trouble sleeping in noisy environments often resort to strategies like earplugs or noise-cancelling headphones that muffle the sound, but a new study from investigators at Massachusetts General Hospital (MGH) may lead to ways to block disturbing sounds within the brain. In their report in the August 10 issue of Current Biology, the team reports finding a brain-wave pattern, reflecting activity of a key structure, that predicts the ease at which sleep can be disrupted by noise.

10 Aug 2010